stocksbrew

Danaher CorporationDHR

Buy more

Buy more on a dip to our buy price, which is under Friday's $221.

  • 4 good· Earnings beat
  • 5 to watch· Profit falling

$220.76−6.80 (−2.99%)

After hours $221.31 +0.4% · 7:37 PM ET on Friday

Price at 3:59 PM ET on Friday

Market closed · opens in 22h 24mNext open: Monday, Nov 23, 9:30 AM ET

NYSE · Healthcare · Life Sciences · Large company

The price we'd buy DHR at comes with a free account

It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.

What would change it

Sources

Could move it to Keep

Next report

  • Shrinking

    sales

Compared with the S&P 500

  • 6 points

    worse in one day

  • 14 points

    worse in five trading days

+0.1% in a year

Earnings report

The news behind our call

written Sep 22, 9:51 AM ETSep 22, 9:51 AM ET · 1 articles · 1 sources

How DHR's risks changed

10-K filed Feb 24 against its 10-K from Feb 20, 2025

−1dropped

Read 1 more
Dropped
  • Our restructuring actions and other cost reduction efforts can have long-term adverse effects on our business and financial statements.

What changed

  1. Yesterday
  2. Did Microsoft AI Partnership just shift Danaher's investment Narrative?

  3. Friday
  4. Is Danaher undervalued after its Microsoft AI Lab Partnership?

  5. Can Danaher hold a premium as bioprocessing markets grow?

  6. Danaher corporation raised its earnings guidance

  7. Danaher down 1% since last earnings report: Can it rebound?

  8. Danaher Teams up with Microsoft to Develop AI-Powered Scientific Instruments

  9. Danaher Collaborates with Microsoft to make Scientific Instruments agentically connected and Laboratories more Intelligent

  10. Wednesday
  11. Danaher targets Faster growth with acquisitions, AI and a Diagnostics push

Overview

Key figures

Revenue (TTM)
$25.6B
Revenue growth, 1 year
+5.5%
Net income
$4.3B
EPS (diluted)
$6.10
Gross margin
59.4%
Operating margin
22.0%
Return on equity
8.2%
Return on capital
7.0%
Debt / equity
0.52
Current ratio
1.63
Dividend yield
0.72%
Buyback yield
1.60%

Revenue by business

period ending Sep 30, 2026
  • Diagnostics$10.5B · 41%
  • Life Sciences$7.6B · 30%
  • Biotechnology$7.6B · 30%

Revenue by region

period ending Sep 30, 2026
  • North America$10.4B · 58%
  • Western Europe$6.3B · 35%
  • Other Developed Markets$1.2B · 6.9%

Key facts

Company value
$155B
Price / last year's earnings
36.2×
Today's range
219.93228.10
Past year's range
161.29240.61
Yesterday's close
$227.56
Swings vs the market
0.8×about the same
Dividend yield
0.72%$1.60 a year

Compare DHR with

Weekend

Still Sunday. Nothing's moving except the clock.

22hrs24min13sec

Market opens Monday, Nov 23 at 9:30 AM ET